Immunic (NASDAQ:IMUX) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Immunic (NASDAQ:IMUX - Free Report) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $17.00 price target on the stock.

A number of other research analysts have also recently issued reports on IMUX. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Immunic in a research note on Friday, February 21st. StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a report on Thursday, March 20th. Finally, William Blair started coverage on Immunic in a research note on Tuesday, March 25th. They issued an "outperform" rating for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $12.67.

Immunic Trading Down 5.4 %

Shares of Immunic stock traded down $0.06 during mid-day trading on Tuesday, reaching $1.05. 844,011 shares of the stock were exchanged, compared to its average volume of 610,716. Immunic has a fifty-two week low of $0.92 and a fifty-two week high of $2.11. The company has a market cap of $94.58 million, a price-to-earnings ratio of -0.85 and a beta of 1.89. The firm has a 50-day simple moving average of $1.09 and a 200 day simple moving average of $1.20.

Remove Ads

Institutional Trading of Immunic

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMUX. Invesco Ltd. acquired a new position in Immunic in the fourth quarter valued at approximately $37,000. Virtu Financial LLC acquired a new position in shares of Immunic in the 3rd quarter valued at $50,000. HB Wealth Management LLC bought a new position in shares of Immunic in the 4th quarter worth $81,000. Barclays PLC bought a new position in shares of Immunic in the 4th quarter worth $84,000. Finally, Jane Street Group LLC grew its stake in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after purchasing an additional 38,553 shares during the period. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.